Review article · 28 Feb 2025
Case reportPublished 25 Nov 2017
Implication of Murphy's Law in Clinical Trials
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Assessment of performance status (PS) is an essential part of inclusion criteria in oncology clinical trials. It correlates with the major study outcomes. Among limitations of PS assessment is lack of well-defined criteria which may lead to difference in interpretation. We present 3 cases of misinterpretation of patients’ clinical condition that lead to different PS assessment. In 2 cases activity of patients was limited due to factors other than oncology disease, recent surgery and concomitant medical condition (obesity). Such situations as presence of concomitant factors that have a potential to limit patient’s ability to perform working or daily living activities, should be carefully considered while assessing PS.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neoplasm.
Short communication · 28 Feb 2025
Cancer Metabolism and Its Therapeutic Implications in Tumor Control
Perspective · 28 Feb 2025
Immuno-Oncology: Harnessing the Immune System against Neoplasms
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neoplasm
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- SubjectSocial Sciences & Humanities
- BylineArticles whose byline prints “Maxim Kosov”
- BylineArticles whose byline prints “Veronika Kolesnik”
- BylineArticles whose byline prints “John Riefler”
- BylineArticles whose byline prints “Maxim Belotserkovskiy”

